Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016

被引:69
作者
Citrin, Deborah E. [1 ]
Prasanna, Pataje G. S. [2 ]
Walker, Amanda J. [3 ]
Freeman, Michael L. [4 ]
Eke, Iris [1 ]
Barcellos-Hoff, Mary Helen [5 ]
Arankalayil, Molykutty J. [1 ]
Cohen, Eric P. [6 ]
Wilkins, Ruth C. [7 ]
Ahmed, Mansoor M. [2 ]
Anscher, Mitchell S. [8 ]
Movsas, Benjamin [9 ]
Buchsbaum, Jeffrey C. [2 ]
Mendonca, Marc S.
Wynn, Thomas A. [10 ]
Coleman, C. Norman [2 ]
机构
[1] Ctr Canc Res, Radiat Oncol Branch, Bethesda, MD USA
[2] NCI, Radiat Res Program, Div Canc Treatment & Diag, Rockville, MD USA
[3] US FDA, Off Hematol & Oncol Prod, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[4] Vanderbilt Univ Sch Med, Dept Radiat Oncol, Nashville, TN USA
[5] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA
[6] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
[7] Hlth Canada, Consumer & Clin Radiat Protect Bur, Radiobiol Div, Ottawa, ON, Canada
[8] Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA USA
[9] Henry Ford Hosp, Dept Radiat Oncol, Detroit, MI 48202 USA
[10] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA
关键词
GROWTH-FACTOR-BETA; BREAST-CANCER PATIENTS; DOUBLE-STRAND BREAKS; PLASMINOGEN-ACTIVATOR INHIBITOR-1; CONVERTING ENZYME-INHIBITORS; LATE RADIOTHERAPY TOXICITY; INDUCED PULMONARY-FIBROSIS; T-LYMPHOCYTE APOPTOSIS; INDUCED LUNG FIBROSIS; TGF-BETA;
D O I
10.1667/RR14784.1
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
A workshop entitled "Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate'' (held in Rockville, MD, September 19, 2016) was organized by the Radiation Research Program and Radiation Oncology Branch of the Center for Cancer Research (CCR) of the National Cancer Institute (NCI), to identify critical research areas and directions that will advance the understanding of radiation-induced fibrosis (RIF) and accelerate the development of strategies to mitigate or treat it. Experts in radiation biology, radiation oncology and related fields met to identify and prioritize the key areas for future research and clinical translation. The consensus was that several known and newly identified targets can prevent or mitigate RIF in pre-clinical models. Further, basic and translational research and focused clinical trials are needed to identify optimal agents and strategies for therapeutic use. It was felt that optimally designed preclinical models are needed to better study biomarkers that predict for development of RIF, as well as to understand when effective therapies need to be initiated in relationship to manifestation of injury. Integrating appropriate endpoints and defining efficacy in clinical trials testing treatment of RIF were felt to be critical to demonstrating efficacy. The objective of this meeting report is to (a) highlight the significance of RIF in a global context, (b) summarize recent advances in our understanding of mechanisms of RIF, (c) discuss opportunities for pharmacological mitigation, intervention and modulation of specific molecular pathways, (d) consider the design of optimal clinical trials for mitigation and treatment and (e) outline key regulatory nonprescriptive frameworks for approval. (C) 2017 by Radiation Research Society
引用
收藏
页码:1 / 20
页数:20
相关论文
共 176 条
[1]   miR-34: from bench to bedside [J].
Agostini, Massimiliano ;
Knight, Richard A. .
ONCOTARGET, 2014, 5 (04) :872-881
[2]   Regulation of radiation-induced apoptosis by early growth response-1 gene in solid tumors [J].
Ahmed, MM .
CURRENT CANCER DRUG TARGETS, 2004, 4 (01) :43-52
[3]   A Preliminary Study on Racial Differences in HMOX1, NFE2L2, and TGFβ1 Gene Polymorphisms and Radiation-Induced Late Normal Tissue Toxicity [J].
Alam, Asim ;
Mukhopadhyay, Nitai D. ;
Ning, Yi ;
Reshko, Leonid B. ;
Cardnell, Robert J. G. ;
Alam, Omair ;
Rabender, Christopher S. ;
Yakovlev, Vasily A. ;
Walker, Linda ;
Anscher, Mitchell S. ;
Mikkelsen, Ross B. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (02) :436-443
[4]   Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma [J].
Albiges, L. ;
Chamming's, F. ;
Duclos, B. ;
Stern, M. ;
Motzer, R. J. ;
Ravaud, A. ;
Camus, P. .
ANNALS OF ONCOLOGY, 2012, 23 (08) :1943-1953
[5]   Association between Normal Tissue Complications after Radiotherapy and Polymorphic Variations in TGFB1 and XRCC1 Genes [J].
Alsbeih, G. ;
Al-Harbi, N. ;
Al-Hadyan, K. ;
El-Sebaie, M. ;
Al-Rajhi, N. .
RADIATION RESEARCH, 2010, 173 (04) :505-511
[6]   Independent prospective validation of a predictive test for risk of radiation induced fibrosis based on the gene expression pattern in fibroblasts irradiated in vitro [J].
Andreassen, Christian Nicolaj ;
Overgaard, Jens ;
Alsner, Jan .
RADIOTHERAPY AND ONCOLOGY, 2013, 108 (03) :469-472
[7]   Pelvic radiation disease [J].
Andreyev, H. J. N. .
COLORECTAL DISEASE, 2015, 17 (01) :2-6
[8]   Guidance: The practical management of the gastrointestinal symptoms of pelvic radiation disease [J].
Andreyev, H. Jervoise N. ;
Muls, Ann C. ;
Norton, Christine ;
Ralph, Charlotte ;
Watson, Lorraine ;
Shaw, Clare ;
Lindsay, James O. .
FRONTLINE GASTROENTEROLOGY, 2015, 6 (01) :53-72
[9]   Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial [J].
Andreyev, H. Jervoise N. ;
Benton, Barbara E. ;
Lalji, Amyn ;
Norton, Christine ;
Mohammed, Kabir ;
Gage, Heather ;
Pennert, Kjell ;
Lindsay, James O. .
LANCET, 2013, 382 (9910) :2084-2092
[10]   Making sense of latent TGFβ activation [J].
Annes, JP ;
Munger, JS ;
Rifkin, DB .
JOURNAL OF CELL SCIENCE, 2003, 116 (02) :217-224